
First quarter 2026
Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.
Press Releases
June 19, 2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
June 19, 2026
Communiqué de presse : Sanofi et HEC Paris lancent la « Sanofi MBA Life Sciences Scholarship » pour accompagner les futurs leaders de la santé
June 12, 2026
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Upcoming Events
18Jun
2026
JPM European Healthcare Forum l London
Conferences
30Jul
2026
Second quarter 2026 results
Second quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on July 30, 2026. The presentation will be followed by a Q&A session.
13:00 - 14:15 CET (7:00am - 8:15am EST)
Quarterly results
9Sep
2026
Kepler Cheuvreux Autumn Conference l Paris
Speaker : Thomas Grenier, Head of North America, Vaccines
Conferences


31st Consecutive Year of Dividend Increase

Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00
